HeyJaredDiabetes Trial Files
Free bimonthly newsletter that summarizes the most significant, practice-changing diabetes randomized controlled trials, straight to your inbox.
- Indexed issues, last 90 days
- 1
- Latest publication
- Aug 6, 2026
- Audience
- Checking…
- Earliest in this view
- Aug 6, 2026
Latest issues
Diabetes Trial Files: Orforglipron vs. Dapa, CagriSema Add-On, and Retatrutide in T2DM (opens the original)
Read excerpt
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2)Welch M et al. The Lancet (July 2026)Bottom Line: This phase 3, multicentre, open-label clinical trial evaluated the efficacy and safety of orforglipron (3 mg, 12 mg, or 36 mg) versus dapagliflozin (10 mg) in adults with type 2 diabetes inadequately controlled by metformin over 40 weeks. A total of 962 participants were randomized, with the primary outcome being the
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.